News Release - July 12, 2006

U.S. Food and Drug Administration (FDA) Approves ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), The First Once-Daily Single Tablet Regimen for Adults with HIV-1 Infection

Source: Gilead Sciences

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.